A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells

Anti-CD20 monoclonal antibodies (mAb) such as rituximab have been proven to be highly effective at improving outcome in B-cell malignancies. However, many patients ultimately relapse and become refractory to treatment. The glycoengineered anti-CD20 mAb obinutuzumab was developed to induce enhanced a...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheadle, E J, Lipowska-Bhalla, G, Dovedi, S J, Fagnano, E, Klein, C, Honeychurch, J, Illidge, T M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508079/
https://www.ncbi.nlm.nih.gov/pubmed/27890931
http://dx.doi.org/10.1038/leu.2016.352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508079/
https://www.ncbi.nlm.nih.gov/pubmed/27890931
http://dx.doi.org/10.1038/leu.2016.352

Ejemplares similares